---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-049298"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2026-10-29T21:00:33+00:00"
generated_at: "2026-10-29T21:02:05.865718+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma receives Nasdaq delisting notice; no 180-day cure period due to prior reverse split

## Summary
- Nasdaq notice dated Oct 23, 2026: PPCB closed below $1.00 minimum bid for the 30 consecutive business days before Oct 21, 2026.
- Company is ineligible for the standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) because it effected a reverse stock split in the prior year.
- Delisting set for Nov 2, 2026 unless Propanc appeals to a Nasdaq Hearings Panel by Oct 30, 2026; the company says it intends to appeal.
- Propanc claims it has cured the bid price deficiency since receiving the notice; appeal would stay delisting pending the Panel's decision.
- Company cites risks: reduced liquidity, fewer investors, loss of registration statement access, and impaired employee equity incentives.

## SEC filing metadata
- accession: 0001493152-26-049298
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2026-10-29T21:00:33+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315226049298/0001493152-26-049298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315226049298/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-049298
- JSON: https://secwatch.observer/filing/0001493152-26-049298.json
- Plain text: https://secwatch.observer/filing/0001493152-26-049298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.